It’s not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

North Dakota lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for residents.

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo ...

Novo Nordisk partners with Variant Bio, paying up to $50M upfront for metabolic disease targets. Some funds will support Indigenous communities that provided data.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

This article introduces the largest foundations in the world, fostering changes and improvements across various sectors to ...